Q-omics provides the consensus-scored CNTNAP3P5 profile across patient tissues and cancer cell-line models. CNTNAP3P5 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in COAD. Among the 18 cancer types available for tumor–normal comparison, CNTNAP3P5 is differentially expressed in 4, with the highest sampling consensus in KICH. Additionally, CNTNAP3P5 RNA expression shows 6,554 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight COAD, KICH, and THYM as cancer lineages where CNTNAP3P5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CNTNAP3P5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CNTNAP3P5 survival associations across molecular data types. CNTNAP3P5 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CNTNAP3P5 RNA expression–survival associations across cancer types. High CNTNAP3P5 expression shows unfavorable associations in COAD, BLCA, LUSC, DLBC and PCPG, but favorable associations in KIRC. The COAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify COAD as the clearest survival context for CNTNAP3P5 RNA expression.
This table summarizes CNTNAP3P5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for CNTNAP3P5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CNTNAP3P5 shows lower tumor expression in KICH, BRCA and HNSC and higher tumor expression in KIRC. The KICH box plot shows higher CNTNAP3P5 RNA expression in normal versus tumor tissue (log2 FC = −0.062, t-test p = .001).
This table shows molecular features associated with CNTNAP3P5 in patient tissues and cancer cell lines. In patient samples, CNTNAP3P5 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
